PT-141
Bremelanotide, a cyclic melanocortin receptor agonist peptide
Melanocortin-receptor agonist research focused on centrally mediated sexual arousal and function.
Route
Subcutaneous.
Common format
10 mg vial
Research focus
hypoactive sexual desire disorder
Evidence level
Strong Human Evidence
Typical cycle
As needed
SexualPT-141 in 30 seconds
Atlas Fast ReadWhat it is
Bremelanotide, a cyclic melanocortin receptor agonist peptide
Why people care
Melanocortin-receptor agonist research focused on centrally mediated sexual arousal and function.
Human evidence
Strong Human Evidence — Substantial randomized or late-phase human evidence with clinically meaningful outcomes, and/or well-established clinical use relevant to the stated claim.
Biggest misconception
Evidence is strongest for its labeled HSDD population. Gaps include broader populations, long-term frequent use, male sexual-dysfunction indications, cardiovascular-risk boundaries, and chronic daily use.
Bottom line
Bremelanotide has real randomized evidence and an FDA-approved sexual-health indication.
Overview
What is PT-141?
PT-141 is bremelanotide, a cyclic melanocortin receptor agonist peptide. Melanocortin-receptor agonist research focused on centrally mediated sexual arousal and function.
Bremelanotide was developed from melanocortin-peptide research after sexual-arousal effects were observed with melanotan analogues. It was approved in the United States in 2019 as Vyleesi for acquired generalized HSDD in certain premenopausal women.
Mechanism
How it works
Activates central melanocortin receptors, especially MC4R-related pathways, increasing neural signaling associated with sexual desire rather than acting primarily through genital vasodilation.
Research areas
Evidence
What does the evidence actually say?
Substantial randomized or late-phase human evidence with clinically meaningful outcomes, and/or well-established clinical use relevant to the stated claim.
Preclinical Evidence
Limited Human Evidence
Strong Human Evidence
Human evidence
Preclinical evidence
Knowledge gaps
Protocol
Research protocol
Dose
Frequency
Timing
Route
Cycle length
Reconstitution
Storage
Monitoring
Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.
Safety
Safety, side effects, and precautions
Side effects
Contraindications
Interactions
Stacks
Common stacks
PT-141 alone under the labeled regimen
The approved evidence base is for bremelanotide as a single agent for a specific HSDD population.
Do not extrapolate to chronic daily or multi-peptide sexual-health stacks.
Questions
FAQ
References
Sources
- Human phase 3 trialsBremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
- FDA prescribing informationVyleesi (bremelanotide) Prescribing Information
- Primary literature indexPubMed literature search: PT-141
- Clinical trials indexClinicalTrials.gov search: PT-141
Atlas
The Atlas verdict
Bremelanotide has real randomized evidence and an FDA-approved sexual-health indication. The evidence supports an as-needed labeled use in a defined population—not the chronic daily dosing and broad male/female performance claims often seen in peptide marketing.